Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALAUNUS: Allogeneic Human Mesenchymal Stem Cell Infusion in Alcohol Use Disorder and Major Depression
NCT03265808Phase 2Completed
- Start
- Mar 2018
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) and major depressive disorder (MDD) comparing allogeneic human mesenchymal stem cells (allo-hMSCs) with Placebo (2 arms). Primary endpoint: Incident of treatment emergent-serious adverse events at 1 month. Started Mar 2018; status: completed.
02
Drugs
allogeneic human mesenchymal stem cells
03
Conditions
alcohol use disorder (AUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03265808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265808.